)
)
This theater will explore new approaches in tumor microenvironment mapping, pathway analysis, liquid biopsy and minimal residual disease. It will highlight recent groundbreaking work on cancer biomarkers, advances in immunotherapy, and strategies to understand and overcome therapeutic resistance.
11:30
-
Variants across coding and non-coding regions mapped and characterized. Downstream analyses reveal previously hidden patterns and potential therapeutic targets. Data opens new avenues for pharma and …
12:00
12:30
-
Y chromosome loss: a hidden player in cancer – why this neglected alteration is gaining attention. Cutting-edge detection methods – from genomics to functional assays. Passenger or driver? – insight …
14:10
-
Mechanistic insights into CNS and bone marrow niches that protect residual breast cancer cells and enable dormancy. Tumor–microenvironment interactions, including immune and stromal co-option, reveal …
14:40
15:10
-
Increased hypoxia leads to activation of fibroblasts and drives desmoplasia in progressive PDAC compared to non-progressive PDAC HIF1A-driven MIF and PLAU signaling from activated fibroblasts and tum …
16:10
-
Beyond static genomics: Integrating clinical, SDOH, genomic, transcriptomic, and spatial data streams into real-time, actionable intelligence. Purpose-built AI agents in oncology: Coordinated, domain …
16:40
-
Understanding how tumour–immune interactions in glioblastoma shape response and resistance to T-cell–based immunotherapies Mapping T-cell differentiation states within the brain tumour microenvironme …
17:10
-
Longitudinal single cell study of multiple tissue compartments from a CAR T cell clinical trial at UPenn. CAR T cell infusion results in widespread immune recruitment and phenotypic change. Among mu …
11:30
-
How liquid biopsy technologies enable earlier cancer detection, and how assay specifications differ prior to diagnosis (screening/early detection) versus after diagnosis (tumour-informed, MRD, and tre …
12:00
12:30
-
Innovating for ultrasensitive ctDNA detection: Technologies that push liquid biopsy beyond current limits by integrating advanced sequencing and in vivo biology‑based approaches to recover rare circul …
14:00
-
Using tumour-informed ctDNA assays for MRD detection in early-stage lung cancer Prognostic value of pre-treatment ctDNA for patient risk stratification ctDNA clearance during therapy as a predictor …
14:30
-
Prospective ctDNA-based minimal residual disease (MRD) assessment during CDK4/6 inhibitor therapy 100% ctDNA detection prior to treatment initiation 28% of on-treatment samples showed detectable tum …
15:00
-
S1826 was a practice-changing randomized phase III trial in patients with newly diagnosed advanced stage classical Hodgkin lymphoma that established a new standard of care. In this study, ctDNA - base …
